BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 26301967)

  • 1. Contribution of chemotherapy mobilization to disease control in multiple myeloma treated with autologous hematopoietic cell transplantation.
    Uy GL; Costa LJ; Hari PN; Zhang MJ; Huang JX; Anderson KC; Bredeson CN; Callander NS; Cornell RF; Perez MA; Dispenzieri A; Freytes CO; Gale RP; Garfall A; Gertz MA; Gibson J; Hamadani M; Lazarus HM; Kalaycio ME; Kamble RT; Kharfan-Dabaja MA; Krishnan AY; Kumar SK; Kyle RA; Landau HJ; Lee CH; Maiolino A; Marks DI; Mark TM; Munker R; Nishihori T; Olsson RF; Ramanathan M; Rodriguez TE; Saad AA; Savani BN; Schiller GJ; Schouten HC; Schriber JR; Scott E; Seo S; Sharma M; Ganguly S; Stadtmauer EA; Tay J; To LB; Vesole DH; Vogl DT; Wagner JL; Wirk B; Wood WA; D'Souza A
    Bone Marrow Transplant; 2015 Dec; 50(12):1513-8. PubMed ID: 26301967
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
    Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
    Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A prospective randomized trial of two popular mononuclear cell collection sets for autologous peripheral blood stem cell collection in multiple myeloma.
    Cooling L; Hoffmann S; Herrst M; Muck C; Armelagos H; Davenport R
    Transfusion; 2010 Jan; 50(1):100-19. PubMed ID: 19719472
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Filgrastim-alone versus pegylated filgrastim-alone for autologous peripheral blood stem cells mobilization in newly diagnosed multiple myeloma patients.
    Skopec B; Skerget M; Zontar D; Zadnik V; Zver S
    Wien Klin Wochenschr; 2017 Aug; 129(15-16):545-551. PubMed ID: 28439700
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beyond CD34+ cell dose: impact of method of peripheral blood hematopoietic stem cell mobilization (granulocyte-colony-stimulating factor [G-CSF], G-CSF plus plerixafor, or cyclophosphamide G-CSF/granulocyte-macrophage [GM]-CSF) on number of colony-forming unit-GM, engraftment, and Day +100 hematopoietic graft function.
    Alexander ET; Towery JA; Miller AN; Kramer C; Hogan KR; Squires JE; Stuart RK; Costa LJ
    Transfusion; 2011 Sep; 51(9):1995-2000. PubMed ID: 21392017
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intermediate-dose versus low-dose cyclophosphamide and granulocyte colony-stimulating factor for peripheral blood stem cell mobilization in patients with multiple myeloma treated with novel induction therapies.
    Hamadani M; Kochuparambil ST; Osman S; Cumpston A; Leadmon S; Bunner P; Watkins K; Morrison D; Speir E; Deremer D; Kota V; Jillella A; Craig M; Awan F
    Biol Blood Marrow Transplant; 2012 Jul; 18(7):1128-35. PubMed ID: 22248715
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Poor peripheral blood stem cell mobilization affects long-term outcomes in multiple myeloma patients undergoing autologous stem cell transplantation.
    Moreb JS; Byrne M; Shugarman I; Zou F; Xiong S; May WS; Norkin M; Hiemenz J; Brown R; Cogle C; Wingard JR; Hsu JW
    J Clin Apher; 2018 Feb; 33(1):29-37. PubMed ID: 28556233
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stem cell mobilization and autologous stem cell transplantation after pretreatment with bendamustine, prednisone and bortezomib (BPV) in newly diagnosed multiple myeloma.
    Poenisch W; Plötze M; Holzvogt B; Andrea M; Schliwa T; Zehrfeld T; Hammerschmidt D; Schwarz M; Edelmann T; Becker C; Hoffmann FA; Schwarzer A; Kreibich U; Gutsche K; Reifenrath K; Schwarzbach H; Heyn S; Franke GN; Jentzsch M; Leiblein S; Schwind S; Lange T; Vucinic V; AlAli HK; Niederwieser D
    J Cancer Res Clin Oncol; 2015 Nov; 141(11):2013-22. PubMed ID: 25976868
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CXCR4 expression on transplanted peripheral blood CD34+ cells: relationship to engraftment after autologous transplantation in a cohort of multiple myeloma patients.
    Hicks C; Isaacs A; Wong R; Chong BH
    Ann Hematol; 2011 May; 90(5):547-55. PubMed ID: 20957366
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modified CVAD and modified CBAD compared to high-dose cyclophosphamide for peripheral blood stem cell mobilization in patients with multiple myeloma.
    Gettys SC; Gulbis A; Wilhelm K; Sasaki K; Dinh Y; Rondon G; Qazilbash MH
    Eur J Haematol; 2017 Apr; 98(4):388-392. PubMed ID: 28009447
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of biosimilar granulocyte colony-stimulating factor versus originator granulocyte colony-stimulating factor in peripheral blood stem cell mobilization in de novo multiple myeloma patients.
    Martino M; Recchia AG; Moscato T; Fedele R; Neri S; Gentile M; Alati C; Vincelli ID; Piro E; Penna G; Musolino C; Ronco F; Molica S; Morabito F
    Cytotherapy; 2015 Oct; 17(10):1485-93. PubMed ID: 26188967
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peripheral blood hematopoietic stem cell mobilization and collection efficacy is not an independent prognostic factor for autologous stem cell transplantation.
    Wang S; Nademanee A; Qian D; Dagis A; Park HS; Fridey J; Smith E; Snyder D; Somlo G; Stein A; Rosenthal J; Falk P; Kogut N; Palmer J; Gaal K; Kim Y; Bhatia R; Yuan S; Kay C; Weiss L; Forman S
    Transfusion; 2007 Dec; 47(12):2207-16. PubMed ID: 17714420
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyclophosphamide plus granulocyte-colony stimulating factor for hematopoietic stem cell mobilization in patients with multiple myeloma.
    Lin TL; Wang PN; Kuo MC; Hung YH; Chang H; Tang TC
    J Clin Apher; 2016 Oct; 31(5):423-8. PubMed ID: 26340986
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autologous/Allogeneic Hematopoietic Cell Transplantation versus Tandem Autologous Transplantation for Multiple Myeloma: Comparison of Long-Term Postrelapse Survival.
    Htut M; D'Souza A; Krishnan A; Bruno B; Zhang MJ; Fei M; Diaz MA; Copelan E; Ganguly S; Hamadani M; Kharfan-Dabaja M; Lazarus H; Lee C; Meehan K; Nishihori T; Saad A; Seo S; Ramanathan M; Usmani SZ; Gasparetto C; Mark TM; Nieto Y; Hari P
    Biol Blood Marrow Transplant; 2018 Mar; 24(3):478-485. PubMed ID: 29079457
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mobilization of Hematopoietic Progenitor Cells with Standard- or Reduced-Dose Filgrastim after Vinorelbine in Multiple Myeloma Patients: A Randomized Prospective Single-Center Phase II Study.
    Samaras P; Rütti MF; Seifert B; Bachmann H; Schanz U; Eisenring M; Renner C; Susanne Müller AM; Schmidt A; Mischo A; Fuchs I; Bargetzi M; Manz MG; Stupp R; Petrausch U; Stenner-Liewen F
    Biol Blood Marrow Transplant; 2018 Apr; 24(4):694-699. PubMed ID: 29246820
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EPO in combination with G-CSF improves mobilization effectiveness after chemotherapy with ifosfamide, epirubicin and etoposide and reduces costs during mobilization and transplantation of autologous hematopoietic progenitor cells.
    Hart C; Grassinger J; Andreesen R; Hennemann B
    Bone Marrow Transplant; 2009 Feb; 43(3):197-206. PubMed ID: 18806833
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized double blind control trial comparing filgrastim and pegfilgrastim in cyclophosphamide peripheral blood hematopoietic stem cell mobilization.
    Kuan JW; Su AT; Wong SP; Sim XY; Toh SG; Ong TC; Rajasuriarr JS; Lim SH; Guan YK; Liew HK; Liew PK; Tan JT; Kori AN; Cheng YY; Tan SM; Chang KM
    Transfus Apher Sci; 2015 Oct; 53(2):196-204. PubMed ID: 25910537
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of biosimilar filgrastim with originator filgrastim for peripheral blood stem cell mobilization and engraftment in patients with multiple myeloma undergoing autologous stem cell transplantation.
    Pham T; Patil S; Fleming S; Avery S; Walker P; Wei A; Curtis D; Stuart G; Klarica D; O'Brien M; Morris K; Das T; Bollard G; Muirhead J; Coutsouvelis J; Spencer A
    Transfusion; 2015 Nov; 55(11):2709-13. PubMed ID: 26173921
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prediction of poor mobilization of autologous CD34+ cells with growth factor in multiple myeloma patients: implications for risk-stratification.
    Costa LJ; Nista EJ; Buadi FK; Lacy MQ; Dispenzieri A; Kramer CP; Edwards KH; Kang Y; Gertz MA; Stuart RK; Kumar S
    Biol Blood Marrow Transplant; 2014 Feb; 20(2):222-8. PubMed ID: 24211319
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mobilization, collection, and transplantation of peripheral blood hematopoietic progenitor cells in a patient with multiple myeloma and hemoglobin SC disease.
    Tormey CA; Snyder EL; Cooper DL
    Transfusion; 2008 Sep; 48(9):1930-3. PubMed ID: 18513256
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.